Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
Chen Li1 12 2,* Long Wan1 12 2,* Jie Luo1 12 2, Mingyan Jiang1 12 2, Keke Wang1 12 2 1Department of Pharmacy, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China; 2School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, P...
Enregistré dans:
Auteurs principaux: | Li C, Wan L, Luo J, Jiang M, Wang K |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4aa5482d9ff0499ea7b5d95e30e82abb |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
par: Lee J, et autres
Publié: (2019) -
Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
par: Kugler AJ, et autres
Publié: (2018) -
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
par: Howell R, et autres
Publié: (2019) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
par: Minara S. Shamkhalova, et autres
Publié: (2020) -
Safety of Semaglutide
par: Mark M. Smits, et autres
Publié: (2021)